Tucatinib
- Generic Name
- Tucatinib
- Brand Names
- Tukysa
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N8O2
- CAS Number
- 937263-43-9
- Unique Ingredient Identifier
- 234248D0HH
- Background
Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
- Indication
本品与曲妥珠单抗和卡培他滨联用治疗人类表皮生长因子受体2(HER2)阳性且已出现转移(如脑转移)或无法进行乳房切除术的乳腺癌成人患者，患者应接受过一种或多种抗HER2乳腺癌药物治疗。
- Associated Conditions
- Breast Cancer, Unresectable Breast Cancer, Wild-type RAS Metastatic Colorectal Cancer, Unresectable RAS Wild Type Colorectal Cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT05253651
- Locations
- 🇺🇸
Pacific Cancer Medical Center Inc., Anaheim, California, United States
🇺🇸Palo Verde Hematology Oncology, Glendale, Arizona, United States
🇺🇸Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Conditions
- HER2-positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05230810
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerAdvanced Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- MedSIR
- Registration Number
- NCT05227131
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 650
- Registration Number
- NCT05132582
- Locations
- 🇨🇱
James Lind Centro De Investigacion Del Cancer, Temuco, Chile
🇨🇳The Second Hospital of Anhui Medical University, Hefei City, Anhui, China
🇩🇪Universitatsklinikum Wurzburg Apotheke, Wurzburg, Germany
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
- Conditions
- HER2-positive Gastric CancerHER2-positive Breast CancerHER2-expressing Non-small Cell Lung CancerHER2-positive Colorectal Cancer
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Silverback Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT05091528
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
- Conditions
- Stage II Colon CancerStage III Colon CancerHER2-positive Colon CancerRAS Wild-type Colon Cancer
- Interventions
- Drug: L-Leucovorin
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 477
- Registration Number
- NCT05062889
- Locations
- 🇮🇹
Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
🇮🇹Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Lecce, Italy
🇮🇹Ospedale San Donato di Arezzo, Arezzo, Italy
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer With a Isolated Brain Progression
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 53
- Registration Number
- NCT05041842
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France
🇫🇷Centre Francois Baclesse, Caen, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Providence Health & Services
- Registration Number
- NCT04896320
- Locations
- 🇺🇸
Providence Newberg Medical Center, Newberg, Oregon, United States
🇺🇸Portland Providence Medical Center, Portland, Oregon, United States
🇺🇸Providence Cancer Institute - Clackamas Clinic, Clackamas, Oregon, United States
Tucatinib Together with Pembrolizumab and Trastuzumab
- Conditions
- Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Breast Cancer Trials, Australia and New Zealand
- Target Recruit Count
- 57
- Registration Number
- NCT04789096
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Macquarie University, Macquarie Park, New South Wales, Australia
🇦🇺Nepean Cancer Care Centre, Kingswood, New South Wales, Australia
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT04721977
- Locations
- 🇰🇷
Seoul National University Hospital ( Site 2003), Seoul, Korea, Republic of
🇯🇵National Cancer Center Hospital ( Site 1003), Tokyo, Japan
🇯🇵Fukushima Medical University Hospital ( Site 1012), Fukushima, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.